|
1
|
Dudeck O and Ricke J: Advances in regional
chemotherapy of the liver. Expert Opin Drug Deliv. 8:1057–1069.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen Y, Yu D, Zhang H, He H, Zhang C, Zhao
W and Shao RG: CD133(+)EpCAM(+) phenotype possesses more
characteristics of tumor initiating cells in hepatocellular
carcinoma Huh7 cells. Int J Biol Sci. 8:992–1004. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance by
preferential expression of the Akt/PKB survival pathway. Oncogene.
27:1749–1758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yamashita T, Ji J, Budhu A, Forgues M,
Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chiba T, Iwama A and Yokosuka O: Cancer
stem cells in hepatocellular carcinoma: Therapeutic implications
based on stem cell biology. Hepatol Res. 46:50–57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wright MH, Calcagno AM, Salcido CD,
Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors
contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell
characteristics. Breast Cancer Res. 10:R102008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Soner BC, Aktug H, Acikgoz E, Duzagac F,
Guven U, Ayla S, Cal C and Oktem G: Induced growth inhibition, cell
cycle arrest and apoptosis in CD133+/CD44+ prostate cancer stem
cells by flavopiridol. Int J Mol Med. 34:1249–1256. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Farhana L, Antaki F, Anees MR,
Nangia-Makker P, Judd S, Hadden T, Levi E, Murshed F, Yu Y, Van
Buren E, et al: Role of cancer stem cells in racial disparity in
colorectal cancer. Cancer Med. 5:1268–1278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weng CC, Kuo KK, Su HT, Hsiao PJ, Chen YW,
Wu DC, Hung WC and Cheng KH: Pancreatic tumor progression
associated with CD133 overexpression: involvement of increased TERT
expression and epidermal growth factor receptor-dependent Akt
activation. Pancreas. 45:443–457. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Koren A, Rijavec M, Kern I, Sodja E,
Korosec P and Cufer T: BMI1, ALDH1A1, and CD133 transcripts connect
epithelial-mesenchymal transition to cancer stem cells in lung
carcinoma. Stem Cells Int. 2016:97143152016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma S, Chan KW, Lee TK, Tang KH, Wo JY,
Zheng BJ and Guan XY: Aldehyde dehydrogenase discriminates the
CD133 liver cancer stem cell populations. Mol Cancer Res.
6:1146–1153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H,
Wicha MS, Chang AE and Li Q: Cytokine-induced killer (CIK) cells
bound with anti-CD3/anti-CD133 bispecific antibodies target
CD133(high) cancer stem cells in vitro and in vivo. ClinImmunol.
149:156–168. 2013.
|
|
13
|
Shao RG and Zhen YS: Enediyne anticancer
antibiotic lidamycin: Chemistry, biology and pharmacology.
Anticancer Agents Med Chem. 8:123–131. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi YK, Wu SY, Huang YH and Zhen YS:
Chemosensitivity of mdr1 gene overexpressed multidrug resistant
cancer cells to lidamycin. Yao Xue Xue Bao. 41:1146–1151. 2006.(In
Chinese). PubMed/NCBI
|
|
15
|
Chen Y, Yu D, Zhang C, Shang B, He H, Chen
J, Zhang H, Zhao W, Wang Z, Xu X, et al: Lidamycin inhibits tumor
initiating cells of hepatocellular carcinoma Huh7 through
GSK3β/β-catenin pathway. Mol Carcinog. 54:1–8. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Griffioen AW, Mans LA, de Graaf AMA,
Nowak-Sliwinska P1, de Hoog CLMM, de Jong TAM, Vyth-Dreese FA, van
Beijnum JR, Bex A and Jonasch E: Rapid angiogenesis onset after
discontinuation of sunitinib treatment of renal cell carcinoma
patients. Clin Cancer Res. 18:3961–3971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang H, Zhang S, He H, Zhao W, Ren K,
Chen J and Shao RG: RasGAP-derived peptide 38GAP potentiates the
cytotoxicity of cisplatin through inhibitions of Akt, ERK and NF-κB
in colon carcinoma HCT116 cells. Cancer Lett. 308:62–70. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang
R, Li J, Zhang Y, Chen L, Qian H, et al: Sphere-forming cell
subpopulations with cancer stem cell properties in human hepatoma
cell lines. BMC Gastroenterol. 11:712011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
de Sousa EM, Vermeulen L, Richel D and
Medema JP: Targeting Wnt signaling in colon cancer stem cells. Clin
Cancer Res. 17:647–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Zhang T, Korkaya H, Liu S, Lee HF,
Newman B, Yu Y, Clouthier SG, Schwartz SJ, Wicha MS and Sun D:
Sulforaphane, a dietary component of broccoli/broccoli sprouts,
inhibits breast cancer stem cells. Clin Cancer Res. 16:2580–2590.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu W, Lin H, Zhang Y, Chen X, Hua B, Hou
W, Qi X, Pei Y, Zhu X, Zhao Z and Yang L: Compound kushen injection
suppresses human breast cancer stem-like cells by down-regulating
the canonical Wnt/β-catenin pathway. J Exp Clin Cancer Res.
30:1032011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu D and Pan W: GSK3: A multifaceted
kinase in Wnt signaling. Trends Biochem Sci. 35:161–168. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhen HY, He QH, Zhen YZ, Wang SL, Liu YN,
Wu WH, Zhang XY, Lu AL and Shen L: Inhibition of mouse embryonic
carcinoma cell growth by lidamycin through down-regulation of
embryonic stem cell-like genes Oct4, Sox2 and Myc. Invest New
Drugs. 29:1188–1197. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yao J, Zhang T, Ren J, Yu M and Wu G:
Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in
vitro growth characteristics of Huh-7 human hepatocarcinoma cells
and U251 human glioma cells. Oncol Rep. 22:781–787. 2009.PubMed/NCBI
|
|
25
|
Fan X, Khaki L, Zhu TS, Soules ME, Talsma
CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al: NOTCH pathway
blockade depletes CD133-positive glioblastoma cells and inhibits
growth of tumor neurospheres and xenografts. Stem Cells. 28:5–16.
2010.PubMed/NCBI
|
|
26
|
Crabtree JS, Singleton CS and Miele L:
Notch signaling in neuroendocrine tumors. Front Oncol. 6:942016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Ye Z, Zheng S, Chen L, Wan Y, Deng
Y and Yang R: Lingo-1 shRNA and Notch signaling inhibitor DAPT
promote differentiation of neural stem/progenitor cells into
neurons. Brain Res. 1634:34–44. 2016. View Article : Google Scholar : PubMed/NCBI
|
